The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
55 | 43 | 54 | 63 |
Growth
|
97 | 13 | 77 | 51 |
Safety
|
18 | 51 | 70 | 19 |
Sentiment
|
31 | 13 | 82 | 63 |
|
47 | 9 | 93 | 35 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
91 | 100 | 100 | 100 |
Opinions Change
|
50 | 50 | 50 | 50 |
Pro Holdings
|
n/a | 1 | 31 | 57 |
Market Pulse
|
20 | 24 | 51 | 52 |
Sentiment
|
31 | 13 | 82 | 63 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
55 | 43 | 54 | 63 |
Growth
|
97 | 13 | 77 | 51 |
|
18 | 51 | 70 | 19 |
Combined
|
69 | 11 | 93 | 96 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
50 | 50 | 50 | 50 |
Price vs. Earnings (P/E)
|
48 | 88 | 73 | 75 |
Price vs. Book (P/B)
|
96 | 24 | 57 | 80 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
55 | 43 | 54 | 63 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
88 | 93 | 85 | 82 |
Profit Growth
|
39 | 1 | 10 | 14 |
Capital Growth
|
96 | 4 | 95 | 75 |
Stock Returns
|
100 | 11 | 81 | 31 |
Growth
|
97 | 13 | 77 | 51 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
14 | 27 | 58 | 62 |
Refinancing
|
63 | 98 | 96 | 28 |
Liquidity
|
4 | 11 | 17 | 6 |
|
18 | 51 | 70 | 19 |
Discover high‑ranked alternatives to The Oncology Institute and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.